文献速递炎症性肠病

纵向不依从预测儿童溃疡性结肠炎治疗升级

Longitudinal non-adherence predicts treatment escalation in paediatric ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2019-08-02

PROTECT研究为前瞻性起始队列多中心研究,纳入268例4-17岁新诊断溃疡性结肠炎患儿,标准化美沙拉秦治疗并电子药瓶监测依从性52周。平均依从轨迹未预测52周无激素缓解,但依从性下降强烈预测治疗升级,第6个月依从率≤85.7%与治疗升级相关。

要点

  • 平均美沙拉秦依从轨迹未预测52周无激素缓解
  • 依从性随时间下降强烈预测治疗升级(β=-.037,P=.001)
  • 第6个月依从率≤85.7%与治疗升级相关

核心结论

  • 不依从可能影响标准化美沙拉秦疗效,从而促成治疗升级需求。
  • 建议治疗开始后至少6个月常规监测依从性并早期处理依从困难。

研究设计与样本

  • PROTECT(NCT01536535)为前瞻性起始队列多中心研究,纳入268例4-17岁新诊断溃疡性结肠炎患儿,随访52周。
  • 患者接受标准化美沙拉秦治疗,预设升级至硫嘌呤或抗TNFα抑制剂标准,使用电子药瓶盖监测依从性。

主要发现

  • 268例患者中,平均美沙拉秦依从轨迹未预测52周无激素缓解。
  • 依从性随时间下降强烈预测治疗升级(β=-.037,P=.001)。
  • 至第6个月,依从率≤85.7%与治疗升级相关。

关键数值与推荐

  • 52周无激素缓解定义为单用美沙拉秦下疾病静止且前≥4周未用糖皮质激素。
  • 治疗升级定义为引入免疫调节剂、钙调神经磷酸酶抑制剂或抗TNFα抑制剂。
  • 第6个月依从率≤85.7%与治疗升级相关。

临床怎么用

  • 对儿童溃疡性结肠炎患者,治疗开始后至少6个月常规监测依从性。
  • 早期识别并处理依从性困难。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medication non-adherence in paediatric ulcerative colitis (UC) has been associated with negative health outcomes including flares in disease activity. However, no studies to date have examined longitudinal adherence to maintenance medication in a prospective controlled trial. AIMS: To determine whether objectively measured adherence to standardised mesalazine (mesalamine) therapy over time was related to remission at 52 weeks and the need for treatment escalation in newly diagnosed paediatric patients with UC METHODS: PROTECT (NCT01536535) was a prospective, inception cohort, multi-site study of paediatric patients aged 4-17 years with newly diagnosed UC followed for 52 weeks. Patients received standardised mesalazine, with pre-established criteria for escalation to thiopurines or anti-TNFα inhibitors. Patients used pill bottles with electronic caps to monitor mesalazine adherence. We tested whether longitudinal adherence to mesalazine predicted steroid-free remission at week 52 (i.e. quiescent disease on mesalazine alone with no corticosteroids ≥4 weeks prior) and need for treatment escalation (i.e. introduction of immunomodulators, calcineurin-inhibitors or anti-TNFα inhibitors). RESULTS: Among 268 patients, average mesalazine adherence trajectories did not predict week 52 steroid-free remission. Declining adherence over time strongly predicted treatment escalation (β = -.037, P = .001). By month 6, adherence rate ≤85.7% was associated with treatment escalation. CONCLUSIONS: Non-adherence may have affected therapeutic efficacy of standardised mesalazine, thereby contributing to need for treatment escalation. Routine adherence monitoring for at least 6 months following treatment initiation and addressing adherence difficulties early in the disease course are recommended.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Carmody JK, Plevinsky J, Peugh JL, et al. Longitudinal non-adherence predicts treatment escalation in paediatric ulcerative colitis. Aliment Pharmacol Ther. 2019. PMID: 31373712. doi:10.1111/apt.15445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。